Impact Factor
7.883
Call For Paper
Volume 12 Issue 07
July 2026
Download Paper Format
Copyright Form
Author(s)
Nakul Ramdas Arjun Kiran Gahininath Wanave Vikram Veer Ravindra Patil
Abstract
When Contrasted With Other Angiotensin II Receptor Blockers, AZL Is Utilized To Treat Fundamental Hypertension And Has Shown Great Outcomes As Far As Circulatory Strain (BP) Decrease And Resilience. Be That As It May, It Has Not Yet Been Incorporated (ARB
Keywords
Azilsartan
UV – Visible Spectrophotometry
RP-HPLC
LC-MS
Validation
Stability Indicating Methods.
Paper ID
IJSARTV8I554682
Publication Date
May 21, 2022
Research Area
Quality Assurance